HbA1c (Glycated Hemoglobin)
HbA1c (Glycated Hemoglobin)
Longitudinal Data
| Date | Value | Flag | Context/Notes | Source |
|---|---|---|---|---|
| 2026-03-02 | 5.7 | N | KIMS - Pre-DM range, improved | Ishamma T M 4.pdf |
| 2025-11-19 | 6.8 | H | DDRC - DM range | 4182YK0075964182_221400g.pdf |
| 2025-07-05 | 6.7 | H | Devi Scans - DM range | ISHAMMA T M 14.pdf |
| 2022-11-25 | 5.8 | H* | JDC Lab (Jothydev's) — HPLC method. Ref <5.7 (facility). Pre-diabetic range by ADA standards. On Tresiba + Trajenta + Glucoformin at time of measurement. (H = flagged by JDC lab ref; pre-DM by ADA) | raw/assets/20260429_IMG_9753.jpeg |
Trend Analysis
Earliest data point (2022-11-25): HbA1c was 5.8% while on full anti-diabetic treatment (insulin Tresiba + Trajenta + Glucoformin), indicating diabetes was medically managed at that point. By July 2025, HbA1c rose to 6.7–6.8% — in the diabetic range — suggesting worsening control or medication changes in the intervening 3 years. By March 2026, HbA1c appeared to improve significantly to 5.7%, now at the upper boundary of normal / lower boundary of pre-diabetic range.
Fructosamine 310 µmol/L (HIGH) measured on Apr 22, 2026 — reference 122–236 µmol/L.
This elevated fructosamine result indicates poor short-term glucose control (1–2 weeks), directly contradicting the "improved" HbA1c of 5.7%.
Interpretation: The HbA1c improvement (6.8% → 5.7%) is spurious, caused by altered RBC turnover from azacitidine/venetoclax treatment. Fructosamine is not affected by RBC turnover and is the more reliable marker in hematologic malignancy.
Conclusion: True diabetes likely persists with poor control. Do not use HbA1c for glycemic monitoring in this patient. Use Fructosamine or home glucose monitoring instead.
See Diabetes Mellitus and Fructosamine for full analysis.